Peak Bio, Inc announced that it has entered into a Common Stock Purchase Agreement with returning investor, White Lion Capital Llc to sell its common stock for the gross proceeds of $100 million on August 24, 2023. The new amendment leaves in place the company?s existing rights, without the obligation, to sell its common stock over a 36-month period but provides for an additional right to sell shares of common stock to White Lion Capital Llc on an accelerated basis where notice and pricing occur on the same trading day.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0086 USD | 0.00% | 0.00% | -95.41% |
03-05 | Akari Therapeutics, Plc entered into a definitive agreement to acquire Peak Bio, Inc.. | CI |
02-16 | Peak Bio, Inc. announced that it has received $2.238 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
-95.41% | 195K | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- PKBO Stock
- News Peak Bio, Inc.
- Peak Bio, Inc. announced that it expects to receive $100 million in funding from White Lion Capital Llc